scPharmaceuticals’ (SCPH) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of scPharmaceuticals (NASDAQ:SCPH) in a report published on Monday,Benzinga reports. HC Wainwright currently has a $18.00 price target on the stock. HC Wainwright also issued estimates for scPharmaceuticals’ FY2029 earnings at $0.70 EPS.

Separately, Craig Hallum reduced their target price on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, November 14th.

scPharmaceuticals Trading Down 3.3 %

Shares of NASDAQ:SCPH opened at $3.18 on Monday. The company has a market cap of $159.13 million, a P/E ratio of -1.67 and a beta of 0.11. The stock’s 50-day moving average is $3.39 and its 200-day moving average is $3.96. scPharmaceuticals has a 52-week low of $3.08 and a 52-week high of $6.20. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08.

Institutional Investors Weigh In On scPharmaceuticals

Hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets lifted its stake in shares of scPharmaceuticals by 116.9% in the third quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock valued at $26,000 after buying an additional 3,101 shares during the period. Legato Capital Management LLC bought a new position in scPharmaceuticals during the fourth quarter worth about $37,000. China Universal Asset Management Co. Ltd. bought a new position in scPharmaceuticals during the fourth quarter worth about $38,000. Virtu Financial LLC bought a new position in scPharmaceuticals during the third quarter worth about $46,000. Finally, ProShare Advisors LLC bought a new position in scPharmaceuticals during the fourth quarter worth about $48,000. Institutional investors own 89.52% of the company’s stock.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.